{"filings":[{"id":806241,"accession_number":"0001493152-26-026879","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K/A","filed_at":"2026-06-02T20:15:28+00:00","items":["9.01"],"status":"ready","headline":"Wellgistics Health issues $21M convertible debt, raises $6.5M new capital, refinances all outstanding convertible debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $21M oversubscribed convertible debt refinances all outstanding convertible debt; no interest; converts at $6.00/share.","Provides $6.5M in new working capital; satisfies closing condition for Datavault AI, Scilex Pharma, and others DelivMeds AI Transaction.","Automatic exchange to Preferred Stock at $50.00/share conversion upon registration effectiveness and shareholder approval (subject to adjustments).","Potential substantial future dilution to existing stockholders upon conversion of the new securities.","Dawson James Securities acted as placement agent for the financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":749277,"accession_number":"0001493152-26-026452","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-29T21:30:04+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health raises $16.9M via convertible notes at 20% OID; majority shareholders lock up shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Notes aggregate principal $21.1M for $16.9M cash (20% OID); zero interest; mature in 12 months.","Conversion price initially lower of $6.00 or 100% of closing price, floor $1.00; later reset to $50 or 100% of closing price.","Warrants to purchase shares at $7.50; expire May 27, 2031; potential cash proceeds ~$39.6M if exercised in full.","Portion of proceeds used to repay ~$1.77M Marco Capital loan.","Holders of 1,333,930 common shares (majority) entered 90-day lock-up; co-CEO cites restructuring confidence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581956,"accession_number":"0001493152-26-024823","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-21T20:10:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"Wellgistics Health announces strategic moves: DelivMeds AI, QOLPOM patents, Tollo Health stake, and share restructuring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expanded Datavault license and DelivMeds AI create IP for tokenized healthcare data management via EinsteinRx™.","QOLPOM patent portfolio adds remote biometric verification and medical drone delivery IP for last-mile rural prescriptions.","Tollo Health controlling interest and Forzet™ enable direct GLP-1 patient engagement through NFL Alumni Health partnership.","Planned share restructuring and new CUSIP to support next phase of growth.","Company believes vertical integration and blockchain will become essential healthcare infrastructure over next decade."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":563517,"accession_number":"0001493152-26-024723","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-21T10:51:51+00:00","items":["1.01","2.03","3.02","3.03","5.03","5.02","9.01"],"status":"ready","headline":"Wellgistics Health enters binding term sheet for DelivMeds AI; announces 1-for-50 reverse stock split","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Binding term sheet with Datavault AI (DVLT), Scilex (SCLX) and others to form DelivMeds AI; combined asset value expected $4B (subject to fairness opinion).","Existing public stockholders projected to retain ~10.4% of common post-conversion; new parties to own ~89.6% via convertible preferred.","Wellgistics to acquire QOLPOM biometric IP from EOS/SCLX, expand PharmacyChain license to HaaS, and acquire controlling stake in Tollo Health (Health Lives Here).","1-for-50 reverse stock split effective May 26, 2026 to regain Nasdaq minimum bid compliance; shares reduce from ~125.7M to ~2.5M.","Note purchase agreement amended: principal increased to $1.5M with additional $200K funding; Gerald Commissiong appointed Interim Co-CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":529076,"accession_number":"0001493152-26-024454","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-19T21:11:19+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Q1 revenue $0.93M, net loss $7.7M; terminates Neuritek/WellCare LOIs; guides Q2 ~$1.78M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.93M in Q1 2026 vs $0.49M Q4 2025; expects Q2 rev $1.78M (with $0.86M recognized through May 18).","Net operating loss $7.74M vs $32.43M prior year; EPS -$0.07 vs -$0.62 on 104.6M shares.","Wellgistics Pharmacy monthly rev grew from ~$0.1M (Nov 2025) to ~$0.6M (Apr 2026).","Terminated non-binding LOIs with Neuritek and WellCare; advanced discussions with Datavault AI for HaaS expansion.","Partnership with Tollo Health and NFL Alumni Health; Health Lives Here app launch targeted Aug 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1559563.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":507996,"accession_number":"0001493152-26-024324","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-19T10:11:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics Health to report Q1 2026 results on May 19 after market close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wellgistics Health will announce Q1 2026 financial results after market close on Tuesday, May 19, 2026.","No preliminary Q1 results or updated guidance have been released in this press release.","The earnings announcement will cover the first quarter ended March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482116,"accession_number":"0001493152-26-024058","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-18T11:20:57+00:00","items":["8.01"],"status":"ready","headline":"Wellgistics withdraws preliminary proxy statement; continues evaluating strategic transactions","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Filed request with SEC to withdraw Preliminary Proxy Statement on Schedule 14A filed May 14, 2026.","Company decided not to proceed with current proxy materials for a special meeting of stockholders.","Wellgistics continues to evaluate potential strategic transactions; may file revised proxy materials later.","No definitive proxy materials were distributed or mailed to stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97352,"accession_number":"0001493152-26-021718","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Wellgistics Health subsidiary enters forbearance agreement on $1.77M debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Wellgistics, LLC acknowledges $1.77M owed to Marco Capital under Nov 2024 loan; MCI forbears through June 15, 2026.","Bi-weekly payments of $50k start May 5, 2026; interest at Term SOFR + 11.5% per annum.","Portion of net proceeds from future financings (10%-30% based on size) must repay debt.","Parent guarantor Wellgistics Health and management (Patel, Sherb) reaffirm guarantees.","Forbearance period ends June 15, 2026 unless earlier triggered by default or financing proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97348,"accession_number":"0001493152-26-021102","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K/A","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Wellgistics Health enters Amended Settlement Agreement with Silverback Capital; no terms disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amended Settlement Agreement with Silverback Capital Corporation dated February 9, 2026.","Agreement amends prior Original Settlement Agreement; no financial or operational terms disclosed.","Filing clarifies this is the material definitive agreement under Item 1.01; prior 8-K date corrected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97347,"accession_number":"0001493152-26-018326","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K/A","filed_at":"2026-04-21T23:59:59+00:00","items":["3.01","1.01","3.02","7.01","9.01"],"status":"ready","headline":"Wellgistics receives Nasdaq deficiency notice; forms JV with KareRx hub","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on Apr 13, 2026 for failing minimum $2.5M stockholders' equity; equity was -$12.4M.","Entered JV with Kare Rx Hub, forming LLC with Wellgistics owning 51%, Kare Hub 49%.","Will pay $2M in unregistered common stock (1.5M shares at closing) for transferred IP and assets.","JV aims to integrate technology platforms to reach 200,000+ patient lives across pharmaceutical and provider networks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97351,"accession_number":"0001493152-26-017895","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health forms joint venture with KareRx Hub, issuing up to $2M in stock for 51% stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Wellgistics holds 51% membership interest in new LLC Healthstar; Kare Rx Hub holds 49%.","Consideration of up to $2M in unregistered common stock: 1.5M shares at closing, additional shares at Wellgistics' option based on VWAP.","Combined platform (EinsteinRx, HubRx AI, KareRx digital hub) aims to reach 200,000+ patient lives.","Partner Kare PharmTech is controlled by Dr. Kiran Patel, founder of WellCare (sold for $200M) and America's 1st Choice Holdings.","Shares subject to 12-month lock-up; closing subject to due diligence and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97350,"accession_number":"0001493152-26-015898","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Wellgistics terminates settlement with Silverback Capital; no further share issuance under Section 3(a)(10)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company terminated Settlement Agreement with Silverback Capital Inc., effective April 3, 2026.","Previously issued 6,866,000 shares of common stock under Section 3(a)(10) pursuant to the settlement.","Termination ends all obligations; no additional shares will be issued and Silverback must return claims to creditors.","Company pursuing alternative strategic and financing initiatives; termination eliminates future dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97349,"accession_number":"0001493152-26-015548","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Wellgistics Health issues $1.25M in promissory notes at 20% discount to accredited investors","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company entered Note Purchase Agreement for up to $1,250,000 aggregate principal; purchase price $1,000,000 (20% OID).","Notes mature in 12 months or upon next Qualified Financing (equity offering); bear 0% interest (15% default rate).","Investors get participation rights in future offerings for at least one year or while notes outstanding.","Company restricted from incurring additional debt or granting liens while notes outstanding.","Offering exempt from registration under Section 4(a)(2) and Rule 506(b); accredited investors only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112028,"accession_number":"0001493152-26-009702","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).","Revenue split: 50% to Wellgistics, 50% to PharmTech; term is 36 months unless earlier terminated.","Wellgistics makes preferred EBV pricing available immediately through EinsteinRx AI hub; expects revenue stream beginning Q2 2026.","EBV market forecast to grow from $2.39B in 2025 to $3B in 2030 per The Business Research Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112027,"accession_number":"0001493152-26-009384","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics launches medical food Forzet for GLP-1 muscle loss targeting $70B market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Forzet is a medical food for dietary management of muscle loss during weight loss therapies, aimed at GLP-1 drug users.","GLP-1 agonist market forecast to grow from $70B (2025) to $201B (2030) per Grandview Research.","Forzet has been evaluated in multiple controlled clinical studies (Type 2 diabetes, heart failure, COPD) in Europe.","Product is classified as medical food, not FDA-approved drug; available OTC under physician supervision.","Initial availability through Wellgistics affiliated pharmacy and select network pharmacies; no revenue guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112026,"accession_number":"0001493152-26-006815","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Wellgistics settles $10.7M liabilities via equity at $0.25–$2.25/share; appoints consulting CBO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settled ~$10.7M liabilities with Silverback Capital via court-approved Section 3(a)(10) share issuance.","Settlement shares priced $0.25–$2.25/share; first $2.25M tranche fixed at $0.25/share.","Issued 400k shares (100k fee + 300k legal) in addition to settlement shares.","Appointed Gerald Commissiong as consulting Chief Business Officer via Fortitude Advisors.","Press release touts Tollo Health telehealth/mental health AI expansion; Forzet distribution expected this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112025,"accession_number":"0001493152-26-005819","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health partners with NFL Alumni Health to deploy AI pharmacy tech for former NFL players","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership leverages EinsteinRx AI platform and PharmacyChain smart contracts for healthcare optimization.","Initial focus on mental health, weight loss, sleep apnea, cardiometabolic disease, pain management, and Long COVID.","Programs first for former NFL players, then expanded to rural communities via Wellgistics' 6,500-pharmacy network.","NFL Alumni Health Ambassadors will promote healthcare access and ease-of-use in rural communities.","Gary Herman elected to board as independent director and appointed Audit Committee chair effective Feb 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112024,"accession_number":"0001493152-26-005387","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Two directors resign from Wellgistics Health board effective Feb 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Lee (Ethics Committee) and Howard Doss (Audit Committee chair) resigned immediately.","Both stated resignations were not due to any disagreement with company operations or practices.","The board now has vacancies; no replacements announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112023,"accession_number":"0001493152-26-002690","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Wellgistics Health issues up to $8.125M secured convertible notes at 20% OID","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $8.125M aggregate principal of secured convertible notes; purchase price $6.5M (20% OID).","Notes bear 0% interest (18% default), mature 6 months or at qualified financing.","Conversion price $0.4057 per share, at holder's election.","Placement agent Dawson James gets 6.5% commission and warrants for 5% of gross proceeds.","Notes secured by assets of Company and subsidiaries; guaranteed by Wood Sage LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112022,"accession_number":"0001493152-26-001001","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health issues $3.125M convertible notes at 20% OID; sets 2026 target of 500 pharmacy onboardings/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued up to $3,125,000 aggregate principal convertible notes; purchase price $2.5M (20% original issue discount).","Notes mature at earlier of 6 months or close of $2M+ qualified equity financing; conversion floor price $0.08.","Placement agent Dawson James Securities received 6.5% commission ($162,500) and warrants for 5% of gross proceeds.","2026 outlook: integrate EinsteinRx AI into pharmacy POS; target onboarding up to 500 pharmacies/month into Wellgistics Pharmacy Network.","Company expanding manufacturer relationships for diabetes, GLP-1, and cardiometabolic drugs; PharmacyChain resource assessment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128665,"accession_number":"0001493152-25-028571","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics sets Dec 19 record date for Dream Bowl meme coin token distribution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date of December 19, 2025 for Dream Bowl 2026 Meme Coin tokens.","Shareholders receive one (1) Dream Bowl token per share of common stock held.","Distribution date and token redemption details to be announced after record date.","Dream Bowl tokens are a meme coin, not a dividend or cash distribution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128664,"accession_number":"0001493152-25-027830","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Wellgistics Health receives Nasdaq bid-price deficiency notice; 180-day cure period through June 8, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1.00 for 30 consecutive business days (Oct 27–Dec 9, 2025); violates Nasdaq Listing Rule 5550(a)(2).","Nasdaq grants 180 calendar days (to June 8, 2026) to regain compliance; eligible for additional 180-day period if other listing standards met.","Company evaluating options, including a potential reverse stock split; no immediate effect on listing under symbol WGRX.","Failure to cure could result in delisting; appeal to Nasdaq hearings panel would be available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128663,"accession_number":"0001493152-25-026652","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics launches Brenzavvy targeting $16B SGLT-2 inhibitor market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brenzavvy launch targets 33M type II diabetics in US with out-of-pocket costs above cash price.","EinsteinRx AI platform alerts pharmacists to patients with Class 1A recommendation for SGLT-2 inhibitors.","Pharmacist-led provider education model aims to improve patient access and create revenue opportunity for pharmacists.","Wellgistics network includes 6,500+ independent pharmacies primarily in rural communities.","SGLT-2 inhibitor market reached $16.8B in 2024; US represents 40.8% of market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128662,"accession_number":"0001493152-25-026358","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics Health declares stockholder distribution of Dream Bowl 2026 Meme Coin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date December 19, 2025; each share receives one Dream Bowl 2026 Meme Coin.","Ex-dividend date December 20, 2025; distribution within 30 days after record date.","Meme coin is a digital collectible for event access, not a security or representing equity.","Dream Bowl 2026 event January 11, 2026 at AT&T Stadium; coordinated with DataVault AI (DVLT)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128661,"accession_number":"0001493152-25-025169","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health sponsors Dream Bowl 2026, plans meme coin airdrop to shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsorship fee of $250,000 for Dream Bowl XIV in Arlington, TX, Jan 8-11, 2026.","Company will distribute Dream Bowl 2026 Meme Coin to shareholders; record and distribution dates expected Dec 2025.","Meme coin airdropped via DataVault AI (NASDAQ: DVLT) wallets; digital collectible not a security.","Partnership includes broadcasting, branding, and CESM intellectual property access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128650,"accession_number":"0001493152-25-025072","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K/A","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics licenses DataVault AI smart contract IP for PharmacyChain; $2.5M upfront plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront license fee of $2.5M due by Dec 31, 2025; ongoing 13% royalty on PharmacyChain net profit.","Minimum annual royalty of $1M from 2028, waived if PharmacyChain net profit under $2M in 2028-2029.","DataVault receives 90% of any sublicensing revenue Wellgistics generates from the licensed IP.","Exclusive license for DataVault's smart contract patents in prescription drug distribution; Wellgistics to build PharmacyChain platform.","Wellgistics expects to integrate with EinsteinRx AI, targeting disruption of PBM rebate system in $634B US drug market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128660,"accession_number":"0001493152-25-024999","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health pays $2.5M for exclusive license of DataVault AI patents for PharmacyChain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License fee of $2.5M to DataVault AI, payable by Dec 31, 2025; plus 13% royalty on net profit from PharmacyChain.","Minimum annual royalty of $1M from 2028 onward, contingent on PharmacyChain achieving $2M annual net profit.","Partnership aims to disrupt $634B US prescription drug industry using blockchain smart contracts and AI hub EinsteinRx.","Wellgistics connects 6,500+ pharmacies and 200+ manufacturers; expects to reduce PBM rebates and improve transparency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128659,"accession_number":"0001493152-25-024471","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.","Loss driven by increased stock-based compensation related to pre-IPO acquisition of pharmaceutical distribution unit.","President/Interim-CEO Prashant Patel reappointed Oct 6; refocusing on EinsteinRx and Brenzavvy diabetes launch.","Acquisition of Peek Healthcare Technologies terminated as no longer strategically aligned.","Advanced discussions with DataVault AI (DVLT) for blockchain license in Q4 2025/Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":21667212.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128658,"accession_number":"0001493152-25-023918","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor UHY resigns citing former CEO resignation info; Suri & Co. re-engaged","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UHY LLP resigned as auditor on Nov 11, 2025 due to information from former CEO's resignation not yet investigated.","UHY did not audit any financial statements; no disagreements or reportable events except previously disclosed material weaknesses.","Audit committee approved re-engagement of Suri & Co. on Nov 17, 2025; Suri had audited 2023 and 2024 financials.","Material weaknesses in internal control over financial reporting were previously reported in Q2 2025 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128657,"accession_number":"0001493152-25-020268","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Wellgistics Health issues ~10.7M shares from warrant exercise and debt conversions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Oct 24, warrant holders exercised 3,111,429 shares at $0.70, raising $2.18M.","On Oct 30, Integra Health debt of $1.3M converted into 1,857,143 shares at $0.70.","On Oct 30, Integra Pharma debt of $4.02M converted into 5,742,656 shares at $0.70.","Total new shares issued: ~10.7 million from these three transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128656,"accession_number":"0001493152-25-019779","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics Health partners with DataVault AI to develop blockchain-based PharmacyChain for prescription drug tracking","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SaaS agreement with DataVault AI (NASDAQ: DVLT) to develop PharmacyChain, a manufacturer-to-patient blockchain platform.","Beta testing expected in first half of 2026; profit-sharing license agreement to be finalized in Q4 2025.","Platform aims to improve prescription tracking, insurance reimbursement, and patient adherence in $639B prescription drug market.","DataVault AI's patents cover blockchain data scoring, valuation, and monetization; platform to enable secure data transfer for pharmacists.","Wellgistics expects PharmacyChain to drive market share gains and expansion into new markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128655,"accession_number":"0001493152-25-018874","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Wellgistics signs non-binding LOI with DataVault for blockchain pharmacy contract platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding LOI to integrate DataVault's blockchain smart contracts (PharmaChain) into Wellgistics' prescription fulfillment network.","Parties contemplate revenue-sharing from pharmacy fees; no definitive agreement yet.","PharmaChain aims to digitize manufacturer-to-patient tracking, improve efficiency and reduce fraud.","Wellgistics will pair PharmaChain with its HubRx AI and 6,500+ pharmacy network.","LOI does not involve token or digital asset issuance; no guarantee of final deal or revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128654,"accession_number":"0001493152-25-018500","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics Health re-appoints Prashant Patel as interim CEO; multiple executive departures","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Prashant Patel re-appointed President, Interim-CEO, and Board member after August 2025 resignation.","Eric Sherb named Interim-CFO; Donald Fell, Steven D. Lee, Howard Doss added to Board.","CEO Brian Norton, CFO Mark DiSiena, COO Tony Madsen depart; board members Shanahan and Peterson also leave.","Patel plans to streamline operations, focus on new revenue opportunities for independent pharmacies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128653,"accession_number":"0001493152-25-017761","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CEO, COO, CFO resign at Wellgistics Health; interim CFO appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brian Norton, COO Tony Madsen, and CFO Mark DiSiena resigned effective Oct. 6, 2025.","Eric Sherb appointed interim CFO on Oct. 7, 2025; he is a CPA with 16 years of experience.","Sherb previously served as CFO of Crown Reserve Acquisition Corp. and Scienture Holdings (SCNX).","Consulting agreement with Sherb's EMS Consulting pays $185/hr for CPA services, $80/hr for bookkeeping.","No permanent replacements named for CEO or COO positions as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128652,"accession_number":"0001493152-25-017134","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Wellgistics Health removes two directors, appoints four new directors and a President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rebecca Shanahan and Michael Peterson removed as directors effective Oct 1, 2025 by majority stockholder consent.","Donald Anderson resigned as director on Oct 2, 2025, citing inability to commit time; no disagreement reported.","New directors Donald Fell, Prashant Patel, Steven D. Lee, and Howard Doss elected Oct 2, 2025; committee assignments set.","Prashant Patel appointed President on Oct 3, 2025; employment agreement with $400,000 annual salary and 3-year term.","New non-employee directors receive $120k annual retainer, 60k annual shares, plus initial 200k restricted shares vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128651,"accession_number":"0001493152-25-016562","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics prices $5M offering (7.14M shares + warrants at $0.70), partners with TheracosBio on Brenzavvy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.","Offering closed Sept 29; H.C. Wainwright acted as placement agent, receiving $350K fee and 500K warrants at $0.875.","Company to use net proceeds for working capital, R&D, and potential acquisitions.","Strategic collaboration with TheracosBio to distribute diabetes drug Brenzavvy (bexagliflozin) via 6,500+ pharmacies starting Q4 2025.","Partnership aims to lower patient costs by bypassing PBMs; Q4 rollout expected to generate near-term revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145418,"accession_number":"0001641172-25-026812","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics Health to present at three investor conferences in September 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Brian Norton will present at H.C. Wainwright 27th Global Investment Conference on Sept 8, 2025.","Also presenting at NIBA Conference (Fort Lauderdale) on Sept 17 and Skyline Signature Series Webinar on Sept 30.","Company's integrated platform connects 6,500+ pharmacies with 200+ manufacturers; no material financial updates provided.","Press release furnished under Item 7.01; corporate presentation and fact sheet also made available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145417,"accession_number":"0001641172-25-026035","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health enters $1.3M loan and launches HubRx AI engine for prescription hub services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $1.3M Business Loan with Agile Capital Funding; matures April 8, 2026; weekly payments of $58,500.","Interest charge of $572,000 assuming timely payments; prepayment penalty equals all interest through maturity.","Used proceeds to pay off prior debts; received ~$500k in cash for working capital, secured by assets.","Launched HubRx AI, a customizable AI engine integrated with LLMs (ChatGPT, Claude, etc.) to automate hub services.","HubRx AI to begin implementation in Q4 2025, full rollout early 2026; targets $5.7B global hub services market by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145416,"accession_number":"0001641172-25-025238","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health Q2 2025 results: H1 pro forma revenue $18.65M, debt conversion strengthens balance sheet","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Pro forma revenue for H1 2025 was $18.65M, up 2.2% from $18.25M in H1 2024.","Converted $10.1M of debt into common stock equity (including $8.6M after June 30) to improve balance sheet flexibility.","Completed operational integration of Wellgistics LLC and Wood Sage LLC, reduced SG&A, upgraded ERP system.","Appointed UHY LLP, a PCAOB-registered auditor, which completed Q2 review; advancing SOC 2 certification.","Expanding DTP programs in diabetes, weight loss, chronic pain; network includes 6,500+ pharmacies and 200 manufacturers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":18654308.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145415,"accession_number":"0001641172-25-024053","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.02","5.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health terminates $50M ELOC, President resigns, launches XRP payment program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated $50M equity purchase agreement with Hudson Global Ventures without penalty; no termination fees.","President Prashant Patel resigned on August 8, 2025; no dispute with management or board.","Launched XRP Implementation Program for independent pharmacies using Ripple's XRP Ledger for instant, low-cost payments.","Program partners with RxERP; serves 6,500+ pharmacies and 200+ manufacturers; beta enrollment open."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145414,"accession_number":"0001641172-25-021455","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health converts $8.1M debt to equity, amends acquisition payment terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Remaining $8.14M closing cash payment converted into 7,606,785 shares of common stock; reduces short-term debt.","Promissory notes increased from $15M to $17.5M; $5M due on first and second anniversaries, $7.5M on third.","Strategix (controlled by CEO Brian Norton) to receive 333,333 shares from prior $1.5M cash payment conversion.","Company will reimburse Sellers $12,000 for fees incurred in connection with the amendments.","Press release says conversion strengthens balance sheet, aims to improve cash flow and expand network."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145413,"accession_number":"0001641172-25-018229","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Wellgistics Health dismisses Suri & Co., appoints UHY LLP as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved dismissal of Suri & Co. on July 7, 2025, and engagement of UHY LLP effective same date.","Suri's reports for FY 2024 and 2023 contained a going concern note but no adverse opinions or disagreements.","No reportable events or disagreements occurred during the covered periods through July 7, 2025.","Suri provided a letter to the SEC dated July 8, 2025, agreeing with the disclosures (Exhibit 16.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163805,"accession_number":"0001641172-25-010557","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Wellgistics Health posts revised investor presentation; no specific changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company updated its investor presentation on its website on May 15, 2025.","Filing states presentation contains forward-looking statements; risks referenced in prior SEC filings.","No financial metrics, guidance updates, or operational details included in the 8-K text.","Exhibit 99.1 (investor presentation) not provided in this filing excerpt; changes unknown."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163804,"accession_number":"0001641172-25-006003","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Wellgistics appoints Mark DiSiena as CFO; Vishnu Balu resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective April 22, 2025; DiSiena succeeds Balu who served since April 2024.","Balu's resignation not due to any dispute with Company, management, or board.","DiSiena receives annual salary of $200K, increasing to $275K upon a min. $10M funding round.","DiSiena granted 150K restricted shares vesting annually starting Dec 31, 2025.","Employment agreement effective 3 years, auto-renewing annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163803,"accession_number":"0001641172-25-005404","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health converts $1.5M debt owed to CEO into 333,333 shares at $4.50 IPO price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Conversion of $1.5M cash payment due June 14, 2025 into 333,333 common shares at $4.50/share.","Shares issued to Strategix Global LLC, an entity controlled by CEO Brian Norton.","New shares subject to 12-month lock-up agreement with limited exceptions.","Amendment to the Wellgistics MIPA dated May 11, 2023, as previously disclosed.","CEO states conversion reflects belief in company's strategic direction and long-term value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163802,"accession_number":"0001641172-25-003835","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health to acquire Peek Healthcare for $2M cash, $6M note, and shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger: Peek acquired for $2M cash (adjusted) + $6M note (4.5% for 3 years) + 1,777,778 shares; 1,270,163 earn-out subject to $8.8M revenue target by Dec 2027.","Peek's digital prescription platform serves >2,500 patients with $1.5M annual revenue; expected to be immediately accretive.","Related party note: $500k from Sansur Assoc. (Chairman's entity), 10% unsecured, due Oct 2025.","ELOC with Hudson Global Ventures for up to $50M over ~24 months at up to 10% discount; commitment fee 152k shares.","Director Sajid Sayed resigns (no disagreement); Michael Peterson appointed independent director and audit committee chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181688,"accession_number":"0001641172-25-000987","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["3.02","7.01","9.01"],"status":"ready","headline":"Wellgistics grants 19.8M shares of restricted stock; reports pro forma 2024 revenue of $45.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted 19,764,108 restricted shares under the 2023 Equity Plan, including 9M to CEO vesting on financial metrics for FY2025-2027.","Pro forma consolidated net sales for 2024 were $45.7M, a 33% increase over 2023, assuming recent acquisitions occurred Jan 1, 2023.","Launched EinsteinRx, an AI-driven decision support software integrated into the Wellgistics Hub prescription platform.","Aims to onboard 5,000 pharmacies by mid-2026 and grow active patient base 10x by year-end.","Plans multiple tech-driven acquisitions and predictive care AI for customer service and benefits verification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181687,"accession_number":"0001493152-25-011154","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Wellgistics Health enters consulting deal with Draper (100k shares) and reports SOC 2 Type 1 compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered consulting agreement with Draper, Inc. for investor relations and business development services; initial term 3 months, automatic monthly renewal.","Compensation includes 100,000 restricted shares immediately, plus 100,000 shares for each subsequent monthly term.","Achieved SOC 2 Type 1 compliance; third-party audit by Sensiba LLP confirmed security, availability, processing integrity, confidentiality, privacy.","Certification strengthens data protection for AI-driven pharmacy solutions and employer-based healthcare models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181686,"accession_number":"0001493152-25-009442","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Wellgistics Health appoints Brian Norton as CEO, partners with Protega to distribute ROXYBOND","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Norton promoted to CEO, succeeding Timothy Canning; no disagreement cited.","Norton's employment agreement: $490k base salary, performance bonus up to 100%, 9M RSUs vesting over 3 years.","Wellgistics LLC collaborates with Protega to distribute ROXYBOND, the first FDA-approved abuse-deterrent IR opioid.","Collaboration includes pharmacist education on abuse-deterrent options and regulatory compliance.","Wellgistics serves over 5,400 independent pharmacies across all 50 states."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181685,"accession_number":"0001493152-25-008723","cik":2030763,"company_name":"Wellgistics Health, Inc.","ticker":"WGRX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Wellgistics Health partners with Tollo Health to market medical foods for GLP-1 side effects and Long COVID","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consulting agreement with Hudson Global Ventures: $250,000 fee + 52,000 shares for 30-day advisory services.","Subsidiary Wellgistics LLC signs agreement with Tollo Health to market Tollo's medical foods for GLP-1 muscle loss and Long COVID.","Tollo's first product is Galectovid, a proprietary medical food for dietary management of viral infections.","GLP-1 drug market cited at $46.7B, expected to grow to $322B by 2034; 16M working-age Americans have Long COVID.","Wellgistics expects cross-selling to grow customer base and become key supplier in GLP-1 and Long COVID markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":21280000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-02-28T23:59:59+00:00|181685"}